Literature DB >> 25341594

Predicting outcomes of neonates born to GBS-positive women who received inadequate intrapartum antimicrobial prophylaxis.

Katsuaki Kojima1, Ryuma Tanaka, Keisuke Nakajima, Nobuyoshi Kurihara, Mari Saito Oba, Yukio Yamashita, Jun Ishihara, Naohisa Yahagi.   

Abstract

We determined the predicting factors of early-onset group B streptococcal (EOGBS) infection in neonates who were born to GBS carrier mothers with inadequate intrapartum antibiotic prophylaxis (IAP). Medical records of all neonates born from January 1, 2008 to April 1, 2010 were reviewed. Inadequate IAP was defined as delivery less than 4 hours (h) after the first administration of antimicrobial. Of 1910 neonates, 273 were born from mothers colonized with GBS, including 69 who received inadequate IAP. Of 69 neonates, nine showed symptoms, including respiratory distress, fever, tachycardia, vomiting, and irritability. Abnormalities in complete blood count (CBC) and C-reactive protein (CRP) were noted in three and four neonates, respectively. Three infants were diagnosed with EOGBS infection confirmed by positive rectal and throat cultures, and all three presented with respiratory distress and CRP abnormalities. Respiratory distress (p=0.0004) and CRP (p=0.0001) offered reliable indicators for detecting EOGBS infections.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25341594

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  2 in total

1.  Management of group b streptococcus-positive pregnant women at maternity homes in JAPAN: a questionnaire survey of compliance among midwives.

Authors:  Kotomi Yamaguchi; Kazutomo Ohashi
Journal:  Matern Health Neonatol Perinatol       Date:  2018-02-05

2.  Vertical transmission of group B Streptococcus and associated factors among pregnant women: a cross-sectional study, Eastern Ethiopia.

Authors:  Tesfaye Assebe Yadeta; Alemayehu Worku; Gudina Egata; Berhanu Seyoum; Dadi Marami; Yemane Berhane
Journal:  Infect Drug Resist       Date:  2018-03-13       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.